✨ Your Portfolio is fetched and updated from zerodha.
Nano Pharmaceuticals

Valiant Laboratories Ltd.

VALIANTLAB

Market Cap
₹287 Cr.
P/E
0.00

Valiant Laboratories Ltd.

Key Ratios

Edit Ratio's
Market cap
Market cap
287 Cr
PE
PE
-
Prom Holding
Prom Holding
74.94 %
ROE (%)
ROE (%)
-
ROCE (%)
ROCE (%)
-0.39
Div Yield (%)
Div Yield (%)
-
Sales
Sales
203 Cr
OPM (%)
OPM (%)
2.66 %
Debt to Equity
Debt to Equity
0.52
View more
Edit Ratio's

About

Valiant Laboratories Ltd. is an Indian API/bulk drug manufacturer focused on producing paracet… Read more
Low
50
52W Range
High
116
  • Valiant Laboratories
  • Trident Lifeline
  • Bafna Pharma

Timeline

Dividend Update Board Meeting Financials

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statement

New
Edit rows

Forensics

3 Yes

Positive for this company

2 Neutral

Neutral for this company

8 No

Negative for this company

3 No Data

Insufficient data to analyse

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Asset Break-Up - Geography Wise

Peer Comparison

Corporate Actions

Consolidated
DATE
DETAILS
Show More
Show Less
Show More
Show Less

FAQs on Valiant Laboratories Ltd. Business

Valiant Laboratories Ltd. is an Indian API/bulk drug manufacturer focused on producing paracetamol in multiple pharmacopeia grades and specialty chemicals. Founded as Bharat Chemicals in 1980, it operates a Tarapur facility with in-house R&D and serves domestic and export pharmaceutical markets.

Valiant Laboratories major competitors are Trident Lifeline, Bafna Pharma, Everest Organics, iStreet Network, Medico Remedies, Sat Kartar Life, Zenotech Laboratorie.
Market Cap of Valiant Laboratories is ₹287 Crs.
While the median market cap of its peers are ₹277 Crs.

Valiant Laboratories seems to be less financially stable compared to its competitors.
Altman Z score of Valiant Laboratories is 2.49 and is ranked 6 out of its 8 competitors.

View FAQ's On Shareprice

Company Filing

2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
Annual Report FY26 FY25 FY24 FY23 FY22 FY21 FY20 FY19 FY18 FY17 FY16 FY15 FY14 FY13 FY12 FY11 FY10
Earnings Release
Investor Presentation
Conference Call
Conference Call SummaryCon Call Summary

Discussions & Analysis

Pharmaceuticals
GLP-1: The Drug Redefining Diabetes, Obesity, and Pharma’s Future - Perpetuity
Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC
Generic Opportunity for Indian Pharma Companies - Anish Moonka
Nutraceuticals- Industry Overview - Value Educator
Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar
Pharma Compliance In-Depth - Amit Rajan
Deep Dive into Pharma Sector - Omkara Capital
How The Pharma Industry Works - PPFAS
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material